The relation between plasma renin activity before treatment and the haemodynamic and clinical responses to converting enzyme inhibition was determined in 100 consecutive patients with severe chronic heart failure who were treated with captopril or enalapril. Initial doses of captopril produced significant increases in cardiac index and decreases in left ventricular filling pressure, mean arterial pressure, mean right atrial pressure, heart rate, and systemic vascular resistance that varied linearly with the pretreatment value for plasma renin activity. In contrast, there was no relation between the pretreatment activity and the magnitude of haemodynamic improvement after 1-3 months of treatment with the converting enzyme inhibitors, and, con-
differ with regards to pretreatment demographic, haemodynamic, or clinical variables.2 Because of the ability of converting enzyme inhibitors to interfere with the renin-angiotensin system early investigators suggested that the responses to captopril and enalapril could be predicted by assessing plasma renin activity before treatment was started.5 -8 Subsequent studies, however, found little relation between plasma renin activity and haemodynamic response and questioned the value of hormonal measurements as a means of selecting patients likely to benefit from treatment.9 -'" A major drawback of all of these previous studies is that they evaluated only the immediate effects of converting enzyme inhibition in small numbers of patients; unfortunately, short term haemodynamic assessments Usefulness of plasma renin activity in predicting haemodynamic and clinical responses of patients treated with captopril and enalapril are of limited value in predicting long term clinical outcome.2 -14 No previous study has examined the usefulness of plasma renin activity in predicting the long term haemodynamic and clinical responses to these drugs in a large series of patients.
In this study we evaluated the relation between plasma renin activity and the haemodynamic and clinical effects of long term converting enzyme inhibition in 100 consecutive patients with severe chronic heart failure.
Patients and methods
The study population consisted of 100 (70 men, 30 women; aged 27-83 (mean 64) years) consecutive patients with severe chronic heart failure who received treatment with the converting enzyme inhibitors, captopril or enalapril, for at least two weeks and who had their plasma renin activity determined before the start of treatment. The cause of heart failure was ischaemic heart disease in 68 patients, primary myocardial disease in 25, and primary mitral or aortic valve regurgitation, or both, associated with severe left ventricular dysfunction in seven, four of whom had undergone valve replacement surgery. All patients had symptoms at rest or on minimal exertion but were evaluated while clinically stable.
HAEMODYNAMIC ASSES SMENT
Each patient received treatment with converting enzyme inhibitors under controlled conditions. For at least five days before entry into the study doses of digoxin and diuretics remained constant, all previous vasodilator drugs were withdrawn, and patients consumed a 2 g sodium diet. After completion of the initial observation period right heart catheterisation was performed with a triple lumen flow directed thermodilution catheter for the measurement of intracardiac pressures, and an arterial cannula was inserted into the radial artery to measure systemic pressures. Thermodilution cardiac outputs were determined in triplicate by a bedside cardiac output computer using iced injectate. Heart rates were derived from a continuously recorded electrocardiogram.
The following haemodynamic variables were determined repeatedly to ensure stability of the pretreatment state before drug administration: mean arterial pressure, heart rate, pulmonary artery and pulmonary capillary wedge pressures, mean right atrial pressure, and cardiac output. Each of the 100 patients received an initial dose of 25 mg of captopril orally, after which all haemodynamic variables were determined every 30 minutes for three hours.
Patients were then treated with either captopril (75-450 mg daily, 86 patients) or enalapril (20-40 mg daily, 14 patients) for the next 1-3 months, during which time doses of digitalis, diuretics, and converting enzyme inhibitors remained unaltered and a 2 g sodium diet was maintained. At the end of the treatment period right heart catheterisation and arterial cannulation were again performed in 83 patients to assess the long term haemodynamic response to treatment; 17 patients did not undergo repeat evaluation because of death (three patients), refusal (three patients), a change in diuretic dosage (five patients), or physician preference (six patients). The protocol for the second haemodynamic evaluation was identical in all respects to that followed for the first study; haemodynamic variables were measured during uninterrupted treatment for three hours after the administration of captopril and for 4-6 hours after the administration of enalapril.
HORMONAL AND CLINICAL DETERMINATIONS
Blood samples for determining plasma renin activity by radioimmunoassay were collected just before the initial dose of captopril. All samples were drawn at a similar time of day, while the patient was receiving a constant 2 g sodium diet, after 4-12 hours lying supine, and 12-24 hours after taking the last dose of diuretic. Under these conditions, the reproducibility of our determinations of plasma renin activity in 52 patients with congestive heart failure on consecutive days was excellent: r= 0-89 for log. During both short term and long term treatment, the haemodynamic responses to converting enzyme inhibition were assessed at peak drug effect on left ventricular filling pressure and systemic vascular resistance (1 0(0-5)h after captopril and 3-0(1-0)h after enalapril).
Patients were divided into three groups based on their pretreatment plasma renin activity: low (< 2 ng/ml/h; < 1-54 mmol/l/h), intermediate (2-6 ng/ml/h; 1-54-4-62 mmol/l/h), and high (> 6 ng/ml/h; > 4-62 mmol/l/h). These ranges were based on normal values in our laboratory (2-6 ng/ml/h (1-54-4-62 mmol/l/h) while the patient was lying supine and taking a salt restricted diet), and is similar to the classification scheme used by others. Fig. 1 ). In contrast, there was no correlation between pretreatment plasma renin activity and the magnitude of the haemodynamic response to long term converting enzyme inhibition (Fig. 1, Table 1 Pretreatment plasma renin activity (ng/ml/h) 
